<DOC>
	<DOC>NCT01294020</DOC>
	<brief_summary>Conversion of stable pediatric allograft recipients from Prograf® immunosuppression to Advagraf® immunosuppression to compare exposure and follow for safety and efficacy over one year.</brief_summary>
	<brief_title>Study to Compare the Pharmacokinetics of Tacrolimus in Stable Pediatric Allograft Recipients Converted From Prograf® to Advagraf®</brief_title>
	<detailed_description>Part C: Continuation of long-term follow-up (from Day 365 onwards). Patients who have completed Part B and to whom continued treatment with Advagraf® is not currently available, will be offered participation in a continuation of long-term follow-up Part C. Part C will continue until Advagraf® becomes available to these patients or these patients' discontinuation, whichever is the earliest. This applies to patients in the following countries: Czech Republic, Germany, Italy and Poland only.</detailed_description>
	<mesh_term>Tacrolimus</mesh_term>
	<criteria>Must be able to swallow intact study medication capsules Received a single solid organ transplant at least 6 months prior to entry into the study The subject's parent(s), or their legal representative(s), has been fully informed and has given written informed consent to participate in the study. The subject has given assent where applicable Has been receiving a Prograf® based immunosuppressive regimen for a minimum of 3 months Negative pregnancy test prior to enrolment (females) Must agree to practice effective birth control during the study Stable whole blood trough levels of tacrolimus in the range of 3.5 15ng/mL (+/0.5ng/mL) and clinically stable in the opinion of the Investigator Previously received a multiple organ transplant Any rejection episode within 3 months prior to enrolment or within the last 6 months that required antilymphocyte antibody therapy, or 2 or more rejection episodes within the last 12 months Currently receiving Rapamycin, Certican or MPA (Myfortic®) Chronic dysfunction of the allograft, in the opinion of the Investigator Major changes in their immunosuppressive regimen within the last 3 months prior to entry into the study The subject is pregnant or breast feeding</criteria>
	<gender>All</gender>
	<minimum_age>5 Years</minimum_age>
	<maximum_age>16 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Transplant</keyword>
	<keyword>Liver</keyword>
	<keyword>Kidney</keyword>
	<keyword>Heart</keyword>
	<keyword>Lung</keyword>
	<keyword>Immunosuppression</keyword>
	<keyword>Advagraf</keyword>
	<keyword>Pharmacokinetics</keyword>
</DOC>